secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005487
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director
--------------------------------------------------------------------------------

- David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.
- Rita Jain, M.D., appointed independent director; brings autoimmune/inflammatory disease drug development expertise.
- Appointments follow RA Capital's nomination rights from July 2025 private placement; CEO Samuel Reich remains on board.
- Company advancing SAB-142, a fully human anti-thymocyte immunoglobulin for type 1 diabetes and autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526005487/0001193125-26-005487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526005487/sabs-20260105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer